Ole Henrik André Brekke
Plus aucun poste en cours
Profil
Ole Henrik André Brekke is a professional who has held several positions in different firms.
He was the Chief Executive Officer at Nykode Therapeutics ASA and Nextera AS, where he worked from 2009 to 2013.
He was also a Director of Research and Development at Affitech A, a Senior Scientist at the University of Oslo, a Senior Project Manager at Birkeland Innovasjon AS, and a Vice President of Immunology at Bio Medisinsk Innovasjon AS.
Additionally, he was a Manager of Research and Development at Invitrogen Dynal AS.
Dr. Brekke graduated and earned his doctorate from the University of Oslo.
Anciens postes connus de Ole Henrik André Brekke
| Sociétés | Poste | Fin |
|---|---|---|
Bio Medisinsk Innovasjon AS
 Bio Medisinsk Innovasjon AS BiotechnologyHealth Technology Bio-Medisinsk Innovasjon AS engages in the development of biotechnology, bio-medical and pharmaceutical businesses. The firm acts as an investor and incubator for start-ups. The company was founded in 2004 and is headquartered in Oslo, Norway. | Corporate Officer/Principal | - |
| University of Oslo | Corporate Officer/Principal | - |
| Invitrogen Dynal AS | Directeur Technique/Scientifique/R&D | - |
Birkeland Innovasjon AS
 Birkeland Innovasjon AS Investment ManagersFinance Birkeland Innovasjon AS (Birkeland) is the technology transfer subsidiary of Inven2 AS in Norway. Established in 2004 as the technology transfer office of the University of Oslo, Norway's largest research institution, Birkeland manages the University's rights to research results that are suitable for commercialization. The firm is located in Oslo and is named for former physics professor Kristian Birkeland, founder of Norsk Hydro (OS: NHY), an international group active in oil and gas, aluminium and the production of fertilizers for agriculture. | Corporate Officer/Principal | - |
Affitech A/S
 Affitech A/S Pharmaceuticals: MajorHealth Technology Affitech A/S engages in the development of human antibody therapeutics. It focuses on human antibodies for cancer such as hematological and solid tumors; and serious inflammatory conditions including rheumatoid arthritis and severe asthma. The firm enters into partnerships and collaborations with biotechnology companies for antibody discovery and development. The company was founded by Søren Mouritsen and Henrik Irgang Elsner on October 1, 1990 and is headquartered in Copenhagen, Denmark. | Directeur Technique/Scientifique/R&D | - |
Formation de Ole Henrik André Brekke
| University of Oslo | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NYKODE THERAPEUTICS | Health Technology |
| Entreprise privées | 5 |
|---|---|
Nextera AS
 Nextera AS Miscellaneous Commercial ServicesCommercial Services Nextera AS provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer. It offers platform for protein engineering and evolution, such as life sciences, drug discovery, and lead optimization fields. The firm’s core competence lies within protein engineering and evolution utilizing its technology to epitope discovery and epitope validation, as well as lead-candidate generation and validation in-vitro. The company was founded by Geir Åge Løset and Inger Sandlie in 2009 and is headquartered in Oslo, Norway. | Commercial Services |
Affitech A/S
Affitech A/S Pharmaceuticals: MajorHealth Technology Affitech A/S engages in the development of human antibody therapeutics. It focuses on human antibodies for cancer such as hematological and solid tumors; and serious inflammatory conditions including rheumatoid arthritis and severe asthma. The firm enters into partnerships and collaborations with biotechnology companies for antibody discovery and development. The company was founded by Søren Mouritsen and Henrik Irgang Elsner on October 1, 1990 and is headquartered in Copenhagen, Denmark. | Health Technology |
Birkeland Innovasjon AS
Birkeland Innovasjon AS Investment ManagersFinance Birkeland Innovasjon AS (Birkeland) is the technology transfer subsidiary of Inven2 AS in Norway. Established in 2004 as the technology transfer office of the University of Oslo, Norway's largest research institution, Birkeland manages the University's rights to research results that are suitable for commercialization. The firm is located in Oslo and is named for former physics professor Kristian Birkeland, founder of Norsk Hydro (OS: NHY), an international group active in oil and gas, aluminium and the production of fertilizers for agriculture. | Finance |
| Invitrogen Dynal AS | |
Bio Medisinsk Innovasjon AS
Bio Medisinsk Innovasjon AS BiotechnologyHealth Technology Bio-Medisinsk Innovasjon AS engages in the development of biotechnology, bio-medical and pharmaceutical businesses. The firm acts as an investor and incubator for start-ups. The company was founded in 2004 and is headquartered in Oslo, Norway. | Health Technology |
